Investors in Baxter International, Inc. have an opportunity to lead a class action lawsuit following significant alleged failures related to the company’s medical devices. According to Robbins Geller Rudman & Dowd LLP, individuals who purchased Baxter common stock between February 23, 2022, and July 30, 2025, may apply to serve as lead plaintiffs in the litigation, which is set to challenge the company under the Securities Exchange Act of 1934.
The case, titled Electrical Workers Pension Fund, Local 103, I.B.E.W. v. Baxter International, Inc., has been filed in the United States District Court for the Northern District of Illinois. The firm has set a deadline of December 15, 2025 for investors to seek this lead plaintiff role. The lawsuit alleges that Baxter and several of its top executives made misleading statements about the safety and efficacy of their Novum IQ Large Volume Pump, which reportedly experienced systemic defects that posed serious risks to patients.
Throughout the class period, the lawsuit claims that Baxter failed to disclose critical information regarding the Novum LVP’s performance issues. These included instances of underinfusion, overinfusion, and complete fluid non-delivery, which could lead to severe patient injuries or fatalities. Furthermore, the company allegedly was aware of multiple device malfunctions and injuries but did not adequately address the underlying design flaws.
On July 31, 2025, Baxter announced a voluntary and temporary pause on shipments and installations of the Novum LVP due to these ongoing issues. The announcement indicated an inability to provide a timeline for resuming shipments, causing the company’s stock price to plummet by more than 22%. This drastic drop reflects the market’s reaction to the news and the potential implications for Baxter’s financial future.
Individuals interested in becoming lead plaintiffs must demonstrate their financial stake in the case and represent the interests of other investors. The Private Securities Litigation Reform Act of 1995 allows for this appointment, enabling the lead plaintiff to guide the litigation process while selecting a legal firm to represent the class.
Robbins Geller Rudman & Dowd LLP is a prominent firm specializing in securities fraud and shareholder litigation. The firm has achieved significant success in recovering funds for investors, with over $2.5 billion secured in 2024 alone from securities-related class actions. Their track record emphasizes their capability to navigate complex legal challenges effectively.
For investors who have suffered substantial losses due to Baxter’s alleged misrepresentations, this class action presents a pivotal opportunity to seek justice. Interested parties can find more information and submit their details through the firm’s website or contact attorneys J.C. Sanchez and Jennifer N. Caringal directly.
With a growing emphasis on accountability in the healthcare sector, this case against Baxter International could set a significant precedent regarding corporate responsibility and patient safety. As the legal proceedings unfold, stakeholders will closely monitor the implications for both the company and its investors.
